(0.32%) 5 116.12 points
(0.31%) 38 357 points
(0.37%) 15 987 points
(-0.98%) $83.03
(5.36%) $2.03
(0.32%) $2 354.80
(0.54%) $27.68
(4.27%) $961.45
(-0.27%) $0.932
(-0.45%) $10.98
(-0.60%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer...
Stats | |
---|---|
本日の出来高 | 1.25M |
平均出来高 | 126 338 |
時価総額 | 20.90M |
EPS | $0 ( 2024-04-04 ) |
次の収益日 | ( $-0.230 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.0140 (1.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Guerin Mark Patrick | Buy | 8 666 | Common Stock |
2024-03-14 | Guerin Mark Patrick | Sell | 2 591 | Common Stock |
2024-03-13 | Guerin Mark Patrick | Sell | 8 666 | Restricted Stock Units |
2024-03-13 | Fruchtman Steven M | Buy | 23 111 | Common Stock |
2024-03-14 | Fruchtman Steven M | Sell | 8 727 | Common Stock |
INSIDER POWER |
---|
75.89 |
Last 95 transactions |
Buy: 2 889 396 | Sell: 191 603 |
ボリューム 相関
Onconova Therapeutics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Onconova Therapeutics Inc 相関 - 通貨/商品
Onconova Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $226 000 |
総利益: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2023 |
収益: | $226 000 |
総利益: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2022 |
収益: | $226 000 |
総利益: | $212 000 (93.81 %) |
EPS: | $-0.880 |
FY | 2021 |
収益: | $226 000 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.960 |
Financial Reports:
No articles found.
Onconova Therapeutics Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。